This article is more than 5 years old. Information may no longer be current.

FDA clears IND application for ProQR’s Usher syndrome treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has cleared an investigational new drug application for QR-421a for Usher syndrome type 2, ProQR Therapeutics announced in a press release.

QR-421a, an investigational RNA-based oligonucleotide, addresses the underlying cause of vision loss in Usher syndrome type 2 and non-syndromic retinitis pigmentosa due to mutations in exon 13 of the USH2A gene, the release said.

The company plans to begin the phase 1/2 STELLAR clinical trial of QR-421a in early 2019. The first-in-human, double-masked, international, randomized study will include approximately 18 adults, with preliminary data expected in mid-2019.

“We are pleased to be advancing QR-421a, our secondary therapy for an inherited retinal disease, into the clinic and continuing the development of our portfolio of transformative RNA medicines for severe genetic rare diseases,” ProQR CEO Daniel A. de Boer said in the release.